IQVIA’s (IQV) Buy Rating Reiterated at Truist Financial

Truist Financial reaffirmed their buy rating on shares of IQVIA (NYSE:IQV) in a research note released on Monday,Benzinga reports. Truist Financial currently has a $263.00 price objective on the medical research company’s stock, up from their prior price objective of $261.00.

Several other equities analysts have also weighed in on IQV. Stephens began coverage on IQVIA in a report on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective for the company. JPMorgan Chase & Co. cut their price target on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th. Robert W. Baird decreased their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, January 21st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a report on Wednesday, December 11th. Finally, William Blair reiterated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Five investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus price target of $251.67.

IQVIA Trading Down 1.6 %

Shares of IQVIA stock opened at $197.64 on Monday. The firm has a market cap of $35.87 billion, a PE ratio of 26.35, a P/E/G ratio of 2.25 and a beta of 1.48. IQVIA has a 1 year low of $187.62 and a 1 year high of $261.73. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.81. The stock has a fifty day moving average price of $200.77 and a 200-day moving average price of $218.81.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities research analysts anticipate that IQVIA will post 10.81 EPS for the current year.

Insider Buying and Selling

In related news, Director John G. Danhakl bought 1,275 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The shares were acquired at an average cost of $200.58 per share, with a total value of $255,739.50. Following the completion of the purchase, the director now directly owns 1,275 shares of the company’s stock, valued at $255,739.50. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 1.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On IQVIA

A number of institutional investors have recently made changes to their positions in IQV. Norges Bank purchased a new position in IQVIA in the fourth quarter worth $336,041,000. Raymond James Financial Inc. bought a new stake in IQVIA during the fourth quarter worth about $236,120,000. American Century Companies Inc. boosted its holdings in shares of IQVIA by 396.0% in the 4th quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company’s stock worth $222,987,000 after purchasing an additional 905,960 shares in the last quarter. FMR LLC increased its position in shares of IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after purchasing an additional 804,963 shares during the last quarter. Finally, B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of IQVIA during the 3rd quarter valued at about $147,683,000. Institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.